Jove
Visualize
Contact Us

Related Experiment Videos

Antiemetic study design: desirable objectives, stratifications and analyses.

I N Olver1

  • 1Royal Adelaide Hospital, North Terrace, Adelaide, South Australia.

The British Journal of Cancer. Supplement
|December 1, 1992
PubMed
Summary

For phase III antiemetic studies, randomized double-blind parallel designs are recommended over cross-over designs. This ensures robust statistical significance by properly accounting for prognostic variables and avoiding carry-over effects in antiemetic research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.

Internal medicine journal·2014
Same author

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2013
Same author

Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Phase II study of acivicin in patients with recurrent high grade astrocytoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2008
Same author

Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.

European journal of cancer (Oxford, England : 1990)·2007
Same author

Why we will need to learn new skills to control cancer.

Internal medicine journal·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Oncology Supportive Care

Background:

  • Establishing optimal antiemetic dosage and safety is crucial before large-scale clinical trials.
  • Phase III studies require rigorous designs to ensure statistical validity and clinical relevance.
  • Antiemetic efficacy and toxicity balance is a key consideration in patient care.

Purpose of the Study:

  • To recommend the optimal study design for phase III antiemetic trials.
  • To compare the merits and drawbacks of parallel versus cross-over designs.
  • To outline essential considerations for robust clinical trial methodology in antiemetic research.

Main Methods:

  • Recommends a randomized, double-blind, parallel-group design for phase III antiemetic studies.

Related Experiment Videos

  • Highlights the importance of randomization and stratification to control for prognostic variables.
  • Discusses the limitations of cross-over designs, particularly concerning carry-over effects and treatment interactions.

    • Main Results:

    • Randomized parallel designs effectively manage both known and unknown prognostic variables.
    • Cross-over designs present challenges in accurately estimating and adjusting for carry-over effects.
    • Study size, pre-planned interim analyses, and appropriate efficacy measures are critical for detecting clinically significant differences.

    Conclusions:

    • Randomized double-blind parallel-group studies are the preferred design for phase III antiemetic trials.
    • Careful consideration of statistical power, prognostic factors, and potential design biases is essential.
    • Objective and subjective efficacy assessments are necessary for a comprehensive evaluation of antiemetic therapy.